p53 as a prognostic factor in stage I breast cancer

British Journal of Cancer

Volumn 72, Issue 3, 1995, Pages 715-719

  Stenmark Askmalm, M ^a   Stal O ^a   Olsen, K ^a   Nordenskjold B ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Breast cancer; Immunohistochemistry; P53

Indexed keywords

ESTROGEN RECEPTOR; PROTEIN P53; TAMOXIFEN;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GRADING; FROZEN SECTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CELL NUCLEUS; COMPARATIVE STUDY; CYTOPLASM; EVALUATION STUDIES; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MIDDLE AGE; NEOPLASM STAGING; PROGNOSIS; PROTEIN P53; SUPPORT, NON-U.S. GOV'T;

EID: 0028984911     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1995.399     Document Type: Article

References (29)

1. ALLRED CD, CLARK GM, ELLEDGE R, FUQUA SA, BROWN RW, CHAMNESS GC, OSBORNE CK, AND MCGUIRE WL (1993). Association of p53 protein expression with tumour cell proliferation rate and clinical outcome in node-negative breast cancer. J, Natl Cancer Inst., 85, 200-206.
2. BARTKOVA J, BARTER J, VOJTESEK B, LUKAS J, REJTHAR A, KOVARIK J, MILLIS RR, LANE DP, AND BARNES DM, (1993). Immunochemical analysis of the p53 oncoprotein in matched primary and metastatic human tumours. Eur. J, Cancer, 29A, 881-886.
3. BLOOM HJG, AND RICHARDSON WW, (1957). Histological grading and prognosis in breast cancer. Br. J, Cancer, 11, 359-377.
4. BOSARJ B, VIALE G, BOSSI P, MAGGIONI M, COGGI G, MURRAY JJ, AND LEE AKC, (1994). Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas. J, Natl Cancer Inst., 86, 681-687.
5. COX DR, (1972). Regression models and life tables. J, R, Stat. Soc. B., 34, 187-220.
6. DAVIDOFF AM, HERNDON II JE, GLOVER NS, KERNS BJM, PENCE JC, GLEHART JD, AND MARKS JR, (1991a). Relation between p53 overexpression and established prognostic factors in breast cancer. Surgery, 110, 259-264.
7. DAVIDOFF AM, KERNS SJM, IGLEHART JD, AND MARKS JR, (1991b). Maintenance of p53 alterations throughout breast cancer progression. Cancer Res., 51, 2005-2610.
8. DOMAGALA W, HARESGA B, SZADOWSKA A, MARKIEWSKI M, WEBER K, AND OSBORN M, (1993). Nuclear p53 protein accumulates preferentially in medullary and high-grade ductal but rarely in lobular breast carcinomas. Am. J, Pathol., 142, 669-674.
9. FISHER CJ, GILLETT CE, VOJTESEK B, BARNES DM, AND MILLIS RR, (1994). Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation. Br. J, Cancer, 69, 26-31.
10. ISOLA J, VISAKORPI T, HOLLI K, AND KALLIONIEMI OP, (1992). Association of overexpression of tumour suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J, Natl Cancer Inst., 84, 1109-1114.
11. JACQUEMIER J, MOLES JP, PENAULT-LLORCA F, ADELAIDE J, TORRENTE M, VIENS P, BIRNBAUM D, AND THEILLET C, (1994). p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR- SSCP results. Br. J, Cancer, 69, 846-852.
12. KAPLAN E, AND MEIER P, (1958). Non parametric estimation from incomplete observations. J, Am. Stat. Assoc., 53, 457-481.
13. KASTAN MB, ONYEKWERE O, SIDRANSKY D, VOGELSTEIN B, AND CRAIG RW, (1991). Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51, 6304-6311.
14. LANE DP, (1992). p53, guardian of the genome. Nature, 358, 15-16.
15. LANE DP, AND BENCHIMOL S, (1990). p53: oncogene or antioncogene. Genes Dev., 4, 1-8.
16. LIPPONEN P, AALTOMAA HJ, SYRJANEN S, AND SYRJANEN K, (1993). p53 protein expression in breast cancer as related to histopathological characteristics and prognosis. Int. J, Cancer, 55, 51-56.
17. LOWE SW, RULEY HE, JACKS T, AND HOUSMAN DE, (1993). p53- dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74, 957-967.
18. MCGUIRE WL, TANDON AK, ALLRED DC, CHAMNESS GC, AND CLARK GM, (1990). How to use prognostic factors in axillary node-negative breast cancer patients. J, Natl Cancer Inst., 82, 1806-1815.
19. ROSEN PP, GROSHEN S, KINNE DW, AND NORTON L, (1993). Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0T2N0M0 patients with long-term follow-up. J, Clin. Oncol., 11, 2090-2100.
20. SILVESTRINI R, BENINI E, DAIDONE MG, VENERONI S, BORACCHI P, CAPPELLETTI V, DI FRONZO G, AND VERONESI U, (1993). p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J, Natl Cancer Inst., 85, 965-970.
21. STENMARK-ASKMALM M, STAL O, FERRAUD L, SUN SF, CARSTENSEN J, AND NORDENSKJOLD B, (1994). Cellular accumulation of p53 protein: an independent prognostic factor in stage II breast cancer. Eur. J, Cancer, 30 A, 175-180.
22. STAL O, DUFMATS M, HATSCHEK T, CARSTENSEN J, KLIN-TENBERG C, RUTQVIST LE, SKOOG L, SULLIVAN S, WINGREN S, AND NORDENSKJOLD B, (1993). S-phase fraction is a prognostic factor in stage I breast carcinoma. J, Clin. Oncol., 11, 1717-1722.
23. STAL O, SKOOG L, RUTQVIST LE, CARSTENSEN JM, WINGREN S, SULLIVAN S, ANDERSSON C, DUFMATS M, AND NORDENSKJOLD B, (1994). S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer. Br. J, Cancer, 70, 1258-1262.
24. SUN XF, CARSTENSEN JM, ZHANG H, STAL O, WINGREN S, HATSCHEK T, AND NORDENSKJOLD B, (1992). Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet, 340, 1369-1373.
25. THOR AD, MOOR DH, EDGERTON SM, KAWASAKI ES, REIHSAUS E, LYNCH HT, MARCUS JN, SCHWARTZ L, CHEN LC, MAYALL BH, AND SMITH HS, (1992). Accumulation of p53 tumour suppressor gene protein: an independent marker of prognosis in breast cancer. J, Natl Cancer Inst., 84, 845-855.
26. VINDELOV LL, CHRISTENSEN U, AND NISSEN NI, (1983). A detergent trypsin method for the preparation of nuclei for flow- cytometric DNA analysis. Cytometry, 3, 323-327.
27. VOGELSTEIN B, (1990). A deadly inheritance. Nature, 348, 681-682.
28. WRANGE O, NORDENSKJOLD B, AND GUSTAVSSON JA, (1978). Cytosol estradiol receptor in human mammary carcinoma: an assay on isoelectric focusing in polyacrylamide gel. Anal. Biochem., 85, 461-475.
29. YONISH-ROUACH E, RESNITZKY S, LOTEM J, SACHS L, KIMCHI A, AND OREN M, (1991). Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interlukin-6. Nature, 352, 345-347.